Patents by Inventor David Norman Deaton

David Norman Deaton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Benzimidazole derivatives
    Patent number: 6455507
    Abstract: Benzimidazole derivatives useful for treating or preventing viral infections such as those caused by herpes viruses or in the treatment of restenosis following surgical techniques. Methods of preparing these benzimidazole derivatives and pharmaceutical compositions containing them are described.
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: September 24, 2002
    Assignee: SmithKline Beecham Corporation
    Inventors: John Charles Drach, Leroy B. Townsend, Frank Leslie Boyd, Jr., Stanley Dawes Chamberlain, Susan Mary Daluge, David Norman Deaton, Marc W. Andersen, George Andrew Freeman
  • BENZIMIDAZOLE DERIVATIVES
    Publication number: 20020094963
    Abstract: The present invention relates to certain bezimidazole derivatives and their use in medical therapy particularly for the treatment or prophylaxis of virus infections such as those caused by herpes viruses. The invention also relates to the preparation of the benzimidazole derivatives and pharmaceutical formulations containing them.
    Type: Application
    Filed: March 17, 2000
    Publication date: July 18, 2002
    Inventors: JOHN CHARLES DRACH, LEROY B. TOWNSEND, FRANK LESLIE BOYD, STANLEY DAWES CHAMBERLAIN, SUSAN MARY DALUGE, DAVID NORMAN DEATON, MARC W. ANDERSEN, GEORGE ANDREW FREEMAN
  • Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to PPAR-gamma
    Patent number: 6294580
    Abstract: A compound having formula (I), wherein A is selected from the group consisting of: (i) phenyl, wherein said phenyl is optionally substituted by one or more halogen atoms, C1-6alkyl, C1-3alkoxy, C1-3fluoroalkoxy, nitrile, or —NR7R8 where R7 and R8 are independently hydrogen or C1-3alkyl; (ii) a 5- or 6-membered hetrocyclic group containing at least one heteroatom selected from oxygen, nitrogen and sulfur; and (iii) a fused bicyclic ring (a), wherein ring C represents a heterocyclic group as defined in point (ii) above, which bicyclic ring is attached to group B via a ring atom of ring C; B is selected from the group consisting of: (iv) C1-6alkylene; (v) —MC1-6alkylene or C1-6alkyleneMC1-6alkylene, wherein M is O, S, or —NR2 wherein R2 represents hydrogen or C1-3alkyl; (vi) a 5- or 6-membered heterocyclic group containing at least one nitrogen heteroatom and optionally at least one further heteroatom selected from oxygen, nitrogen and sulfur and optionally substituted by C1-3alkyl; and (vii) H
    Type: Grant
    Filed: August 25, 1998
    Date of Patent: September 25, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Timothy Mark Willson, Robert Anthony Mook, Istvan Kaldor, Brad Richard Henke, David Norman Deaton, Jon Loren Collins, Jeffrey Edmond Cobb, Marcus Brackeen, Matthew Jude Sharp, John Mark O'Callaghan, Greg Alan Erickson, Grady Evan Boswell
  • Formamides as therapeutic agents
    Patent number: 6172064
    Abstract: A family of compounds having the general structural formula where W is a reverse hydroxamic acid group, and R1, R2, R3, R4, R5 and R6 are as described in the specification, or a pharmaceutically acceptable salt, solvate, biohydrolyzable ester, biohydrolyzable amide, affinity reagent, or prodrug thereof. Also described are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine.
    Type: Grant
    Filed: August 25, 1999
    Date of Patent: January 9, 2001
    Assignee: Glaxo Wellcome Inc.
    Inventors: Robert Carl Andrews, Marc Werner Andersen, David John Cowan, David Norman Deaton, Scott Howard Dickerson, David Harold Drewry, Michael David Gaul, Michael Joseph Luzzio, Brian Edward Marron, Michael Howard Rabinowitz